By submitting this form, you are agreeing to the Terms of Use and Privacy Policy.
Patients who are in ketosis are diagnosed and monitored with a beta-hydroxybutyrate (BHB) analyzer (also known as ketoacidosis and diabetic ketoacidosis or DKA). When the body starts to break down its fat reserves in reaction to a lack of energy, it enters a state known as ketosis (glucose).
Beta-hydroxybutyrate can also be used to clinically detect and track the presence and severity of conditions such alcoholism, glycogen storage disease, high fat/low carbohydrate diets, pregnancy, alkalosis, isopropyl alcohol consumption, and salicylate poisoning.
Increased blood -hydroxybutyrate levels can be seen in a number of ailments linked to insulin shortage, metabolic substrate utilisation disorders, and altered redox state, such as the following. Diabetes-related ketoacidosis: Dehydration and a lack of insulin both increase the formation of ketone bodies.
The Global Beta-Hydroxybutyrate (BHB) Analyzer market accounted for $XX Billion in 2023 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.
EKF Diagnostics, a business that provides in vitro diagnostics, has announced the global release of their Stat-Site WB handheld analyzer, which provides measures of -ketone and glucose from whole blood in a matter of seconds.
The dual-purpose, portable analyzer is made for business use in the treatment of diabetes patients. Beta-Hydroxybutyrate, or BHB, and glucose are measured quantitatively using the device in whole blood drawn from capillary or venous samples.
The reagent-free, simple analyzer uses two distinct test strips to produce answers for -ketones in 10 seconds and glucose in 5 seconds. As a result, diabetic patients who exhibit early ketosis signs can be managed in a straightforward and thorough manner, ensuring prompt treatment and ongoing monitoring.
